消化

订阅

MedSci主页 / 所有栏目 / 消化

美国FDA批准ABX464进行临床试验以治疗中重度溃疡性结肠炎

2020-01-21 Allan MedSci原创

ABX464中重度溃疡性结肠炎UC
关注

生物技术公司ABIVAX今天宣布，美国FDA已批准了研究性新药（IND）申请，允许在美国使用其主要候选药物ABX464进行临床试验以治疗中度至重度溃疡性结肠炎（UC）。预计首批美国患者将在2020年第二季度入组。

生物技术公司ABIVAX今天宣布，美国FDA已批准了研究性新药（IND）申请，允许在美国使用其主要候选药物ABX464进行临床试验以治疗中度至重度溃疡性结肠炎（UC）。预计首批美国患者将在2020年第二季度入组。

ABX464目前正在15个欧洲国家和加拿大被测试治疗中重度UC的有效性和安全性。这项正在进行中的IIb期临床试验（ABX464-103）现在将扩展至美国。12个月开放标签的最新数据显示，有75％的中度至重度活动性UC患者在免疫调节剂和/或皮质类固醇激素治疗失败后，经ABX464治疗得到临床缓解（基本上无症状）。在所有临床试验中，ABX464都是安全且耐受性良好的，没有严重的药物不良反应。不良事件的强度通常为轻度到中度，最常见不良反应为头痛、腹痛和腹泻。


原始出处：

https://www.firstwordpharma.com/node/1694810?tsid=4

本文系梅斯医学（MedSci）原创编译整理，转载需授权!

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1695138, encodeId=0aea169513819, content=<a href='/topic/show?id=c76e6645438' target=_blank style='color:#2F92EE;'>#溃疡性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66454, encryptionId=c76e6645438, topicName=溃疡性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=787129789891, createdName=nymo, createdTime=Fri Mar 13 17:27:00 CST 2020, time=2020-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036558, encodeId=c77a203655866, content=<a href='/topic/show?id=0e771e922b' target=_blank style='color:#2F92EE;'>#ABX464#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1792, encryptionId=0e771e922b, topicName=ABX464)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sun Jun 28 11:27:00 CST 2020, time=2020-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839763, encodeId=11d41839e6396, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Thu Jun 04 03:27:00 CST 2020, time=2020-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551463, encodeId=94d8155146313, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79716, encryptionId=5d84e9716c0, topicName=美国FDA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a46914191431, createdName=10518098zz, createdTime=Thu Jan 23 01:27:00 CST 2020, time=2020-01-23, status=1, ipAttribution=)]
    2020-03-13 nymo

    #溃疡性#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1695138, encodeId=0aea169513819, content=<a href='/topic/show?id=c76e6645438' target=_blank style='color:#2F92EE;'>#溃疡性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66454, encryptionId=c76e6645438, topicName=溃疡性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=787129789891, createdName=nymo, createdTime=Fri Mar 13 17:27:00 CST 2020, time=2020-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036558, encodeId=c77a203655866, content=<a href='/topic/show?id=0e771e922b' target=_blank style='color:#2F92EE;'>#ABX464#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1792, encryptionId=0e771e922b, topicName=ABX464)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sun Jun 28 11:27:00 CST 2020, time=2020-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839763, encodeId=11d41839e6396, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Thu Jun 04 03:27:00 CST 2020, time=2020-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551463, encodeId=94d8155146313, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79716, encryptionId=5d84e9716c0, topicName=美国FDA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a46914191431, createdName=10518098zz, createdTime=Thu Jan 23 01:27:00 CST 2020, time=2020-01-23, status=1, ipAttribution=)]
    2020-06-28 juliusluan78

    #ABX464#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1695138, encodeId=0aea169513819, content=<a href='/topic/show?id=c76e6645438' target=_blank style='color:#2F92EE;'>#溃疡性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66454, encryptionId=c76e6645438, topicName=溃疡性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=787129789891, createdName=nymo, createdTime=Fri Mar 13 17:27:00 CST 2020, time=2020-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036558, encodeId=c77a203655866, content=<a href='/topic/show?id=0e771e922b' target=_blank style='color:#2F92EE;'>#ABX464#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1792, encryptionId=0e771e922b, topicName=ABX464)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sun Jun 28 11:27:00 CST 2020, time=2020-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839763, encodeId=11d41839e6396, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Thu Jun 04 03:27:00 CST 2020, time=2020-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551463, encodeId=94d8155146313, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79716, encryptionId=5d84e9716c0, topicName=美国FDA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a46914191431, createdName=10518098zz, createdTime=Thu Jan 23 01:27:00 CST 2020, time=2020-01-23, status=1, ipAttribution=)]
    2020-06-04 bugit

    #FDA批准#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1695138, encodeId=0aea169513819, content=<a href='/topic/show?id=c76e6645438' target=_blank style='color:#2F92EE;'>#溃疡性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66454, encryptionId=c76e6645438, topicName=溃疡性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=787129789891, createdName=nymo, createdTime=Fri Mar 13 17:27:00 CST 2020, time=2020-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036558, encodeId=c77a203655866, content=<a href='/topic/show?id=0e771e922b' target=_blank style='color:#2F92EE;'>#ABX464#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1792, encryptionId=0e771e922b, topicName=ABX464)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sun Jun 28 11:27:00 CST 2020, time=2020-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839763, encodeId=11d41839e6396, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Thu Jun 04 03:27:00 CST 2020, time=2020-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551463, encodeId=94d8155146313, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79716, encryptionId=5d84e9716c0, topicName=美国FDA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a46914191431, createdName=10518098zz, createdTime=Thu Jan 23 01:27:00 CST 2020, time=2020-01-23, status=1, ipAttribution=)]
    2020-01-23 10518098zz

    #美国FDA#

    0

相关资讯

Abivax将在两个会议上介绍其先导化合物ABX464的全新临床数据

Abivax是一家临床阶段的生物制药公司，利用免疫系统为患有炎症、自身免疫性疾病、病毒感染和癌症的患者开发新型治疗方法，近日宣布将在两个重要会议上公布ABX464治疗炎症性疾病和艾滋病的作用机制的研究数据。

Sci Rep：ABX464独特的作用机制，同时产生抗炎和抗病毒作用

Abivax是一家临床阶段的生物制药公司，利用免疫系统为炎症/自身免疫性疾病和病毒性疾病以及癌症患者开发新的治疗方法，近日发表了新的数据表征其主要候选药物ABX464的作用机制。